Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502.

@article{Seto2010PhaseIT,
  title={Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502.},
  author={Takashi Seto and Takeharu Yamanaka and Izumi Wasada and Nobuhiko Seki and Hiroaki Okamoto and Takashi Ogura and Masahiko Shibuya and Yuichi Takiguchi and Tetsu Shinkai and N. Masuda and Yukito Ichinose and Kenji Eguchi and Koshiro Watanabe},
  journal={Lung cancer},
  year={2010},
  volume={69 2},
  pages={213-7}
}
A phase I/II trial of TS-1 combined with gemcitabine was designed to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate the efficacy and toxicity in elderly patients with advanced non-small cell lung cancer (NSCLC). Patients older than 70 years of age received TS-1 orally b.i.d. on days 1-14 and gemcitabine intravenously on… CONTINUE READING